Nav1.7 anal­gesic fail­ures stack up as Bio­gen aban­dons vixot­rig­ine af­ter lat­est set­back

A slate of drug de­vel­op­ers have re­port­ed fail­ures in tri­als test­ing Nav1.7 in­hibitors for pain man­age­ment, call­ing in­to ques­tion the promise of the class of anal­gesics. On a con­fer­ence call on Tues­day, Bio­gen dis­closed that it was aban­don­ing vixot­rig­ine for sci­at­i­ca pain af­ter the ex­per­i­men­tal drug flopped in a study, adding to a string of fail­ures al­ready di­vulged by oth­er drug­mak­ers, in­clud­ing Roche, Te­va and Xenon.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER